Gene Therapy, Genome Editing and Circadian Biology
This community focuses on developing genetic therapies for rare diseases and understanding the molecular mechanisms of the body's internal clock.
The work centers on three distinct but related areas. First, the development of gene therapies and enzyme replacement treatments for specific conditions, with a heavy emphasis on Pompe disease and alpha-1 antitrypsin deficiency. This involves the use of adeno-associated viruses (AAV) and hematopoietic stem cells to deliver functional genes or correct defects. Second, the application of genome editing tools, particularly CRISPR-Cas9 and zinc finger proteins, to modify DNA and regulate gene expression in human and mouse models. Third, the study of circadian clock genes and their role in physiology, including how disruptions to this timing system affect health and disease. These threads are connected by the shared use of molecular biology techniques to manipulate genetic information for therapeutic or mechanistic insight.
The community is most prominent in research tracked for Zinc, where it constitutes 0.2% of all Zinc-related papers, and Sodium, where it accounts for 0.1% of Sodium-related papers. It also appears in research for Phosphorus, Sulfur, Oxygen, Calcium, Nitrogen, and Bromine, with smaller shares in each.
There are 17,038 papers in this community, with the majority published in the Journal of Biological Chemistry, Molecular Therapy, and Human Gene Therapy.
Recent work includes the development of retargeted serine integrases for precise DNA integration in human cells, the use of hematopoietic stem cell gene editing to create B lymphocyte protein factories, and the study of direct cell-to-cell transmission of retrotransposons.